Company Oxygen Biotherapeutics Inc Nasdaq
Equities
US69207P3082
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14/21/14 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/21/15 |
Doug Randall
COO | Chief Operating Officer | - | 14/13/14 |
Douglas Hay
LAW | General Counsel | - | 14/13/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04/14/04 |
June Almenoff
BRD | Director/Board Member | 67 | 25/21/25 |
Declan Doogan
BRD | Director/Board Member | 72 | 25/21/25 |
Michael Davidson
BRD | Director/Board Member | 67 | 25/21/25 |
Robyn Hunter
BRD | Director/Board Member | 62 | 28/22/28 |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/21/15 |
Chief Executive Officer | 50 | 14/21/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 210 | 0 | 0 | 99.65 % |
Stock B | 1 | 1,958,245 | 1,951,298 ( 99.65 %) | 0 |
Company contact information
Tenax Therapeutics, Inc.
101 Glen Lennox Drive Suite 300
27517, Chapel Hill
+(919) 855-2100
http://www.tenaxthera.comSector
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.4B | |
+46.23% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- TENX Stock
- Stock
- Company Oxygen Biotherapeutics Inc